Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZANGEA phase II study of zanidatamab with pembrolizumab and chemotherapy in HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma
2025-522718-22-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival rate at 12 months. Planned start Nov 2025; status: authorised.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-522718-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522718-22-00.